BioAge Labs, a Phase 2 biotech developing small molecule therapies for metabolic diseases, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.
The company's leading candidate, azelaprag, is an orally available small molecule that has shown encouraging results in preclinical and early clinical trials, particularly in enhancing weight loss when combined with GLP-1R agonists. Beyond weight loss, azelaprag may also improve body composition and muscle function by leveraging a unique technology platform and proprietary human datasets to identify promising targets linked to molecular changes associated with aging. BioAge Labs is currently conducting Phase 2 clinical trials to evaluate azelaprag's potential when combined with existing obesity treatments, aiming to develop an all-oral combination therapy for obesity. Topline data from the first of these trials is expected in the 3Q25. It is also advancing brain-penetrant NLRP3 inhibitors for neuroinflammation-driven diseases, with plans to submit an IND in the 2H25.
The Richmond, CA-based company was founded in 2015 and plans to list on the Nasdaq under the symbol BIOA. BioAge Labs filed confidentially on May 31, 2024. Goldman Sachs, Morgan Stanley, Jefferies, and Citi are the joint bookrunners on the deal. No pricing terms were disclosed.
